2021 American Transplant Congress
Impact of Donation After Circulatory Death Donor Allografts on Outcomes Following Liver Transplantation for Cholangiocarcinoma
*Purpose: Improvements in the management of extra-hepatic cholangiocarcinoma (CCA) resulted in allocation of a standardized model for end-stage liver disease (MELD) exception score for liver…2021 American Transplant Congress
Cancer Among Kidney Transplant Recipients More Than 20 Years After Transplantation: PTLD Remains the Most Common Cancer Type Even in the Very Long-Term
Nephrology, University Hospital Zurich, Zurich, Switzerland
*Purpose: Due to an improved patient and kidney allograft survival, cancer is increasingly recognized as the major cause of death after kidney transplantation. Cancer risk…2021 American Transplant Congress
Treg Lymphotoxin Engages Lymphotoxin Receptor on Cancer and Endothelial Cells to Promote Cancer Metastatic Migration: Mechanisms for Treg-Cancer Interactions
*Purpose: Treg immune suppression which is critical for transplant graft survival may also enhance tumor growth and metastases. Treg lymphotoxin (LTα1β2) may directly engage the…2021 American Transplant Congress
Long Term Survival After Liver Transplantation for Advanced, Unresectable Intrahepatic Cholangiocarcinoma
1Houston Methodist Hospital, Houston, TX, 2MD Anderson Cancer Center, Houston, TX
*Purpose: Intrahepatic cholangiocarcinoma (ICCA) has traditionally been considered a contraindication to liver transplantation (LT). We previously reported a case series of six patients with large,…2021 American Transplant Congress
Associations of Mammalian Target of Rapamycin Inhibitors with Post-Transplant Malignancies and All-Cause Mortality: Cause-Specific Competing Risks and Composite Outcomes Analyses
1University of Florida, Gainesville, FL, 2University of Rhode Island, Kingston, RI
*Purpose: We investigated the outcomes of malignancies and mortality associated with mammalian target of rapamycin inhibitor (MTORI) regimens in adult kidney transplant (KT) recipients (KTRs).*Methods:…2021 American Transplant Congress
Posttransplant Malignancy in HIV+ Kidney Transplant Recipients
*Purpose: Kidney transplant recipients and people living with HIV are both at increased risk for malignancy, including cancers that are virally-mediated. Despite the recognition of…2021 American Transplant Congress
Development of De-novo Malignancies After Kidney and/or Pancreas Transplantation in Diabetic Patients
SUNY Downstate Medical Center, Brooklyn, NY
*Purpose: Transplantation of a kidney (KTA), pancreas (PTA), or a simultaneous pancreas-kidney (SPK) in a patient with end-stage organ failure is a lifesaving treatment. Patient…2021 American Transplant Congress
Prostate Cancer Mortality is Not Worse Among Kidney Transplant Recipients Compared to Dialysis Patients
*Purpose: Recent recommendations from expert panel of American Society of Transplantation (AST) state that most patients with prostate cancer (PCa) do not need to wait…2021 American Transplant Congress
Review of Outcomes After Diagnosis of Malignancy in Kidney Transplant Patients: Unos Database
*Purpose: Malignancy is the third major cause of death among transplant recipients. Among the transplant recipients, Patient and kidney transplant outcomes after the diagnosis of…2021 American Transplant Congress
Cancer-Specific Mortality in Solid Organ Transplant Recipients with a Prior Cancer Diagnosis
*Purpose: A history of cancer is increasingly common among solid organ transplant candidates, and transplant-associated immunosuppression may increase recurrence risk. We assessed whether transplantation was…
- 1
- 2
- 3
- …
- 17
- Next Page »